Gencor is entering the U.S. probiotics market as exclusive agent for a new, patented technology that maintains product stability under extreme conditions, allowing for a wide range of applications. The technology, called Intelicaps, embeds probiotics in a nourishing matrix of microspheres. At the same time, due to layer-by-layer coating, the probiotics are protected against environmental impacts and benefit from long-lasting stabilization. The microcapsules resist low pH levels, making it possible for them to pass through the stomach without opening, and deliver the viable probiotics directly to the intestine, which is the target organ. The new technology was developed by Belgium pharmaceutical company Vesale Pharma.
The Intelicaps technology makes numerous formulations possible, including simple tablets and chewables, as well as safe combinations with substances such as zinc, citrate and vitamin C, according to the company. For more information: www.gencorpacific.com